Rituximab for the treatment of autoimmune cytopenias

Berentsen, Sigbjørn

doi:10.3324/haematol.11312

Cited by 25 publications

(20 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rituximab has also been effective for the treatment of autoimmune cytopenias. [186][187][188][189][190][191][192] Corticosteroids tend to be less effective in PRCA than in ITP or AIHA. If corticosteroids are not effective, cyclosporin can be used.…”

Section: Supportive Care For Patients With Cllmentioning

confidence: 99%

Non-Hodgkin's Lymphomas

Zelenetz

Abramson

Advani

et al. 2011

J Natl Compr Canc Netw

164

View full text Add to dashboard Cite

show abstract

Section: Supportive Care For Patients With Cllmentioning

confidence: 99%

Non-Hodgkin's Lymphomas

Zelenetz

Abramson

Advani

et al. 2011

J Natl Compr Canc Netw

164

View full text Add to dashboard Cite

show abstract

“…Case reports and retrospective analyses have indicated favorable responses to rituximab in patients with refractory AIHA. 78 First-line therapy with steroids is recommended for ITP. Similarly, IVIg, cyclosporin, splenectomy, and rituximab can be effective in treating steroidrefractory ITP.…”

Section: Autoimmune Cytopeniasmentioning

confidence: 99%

Non-Hodgkin’s Lymphomas

Ad¹,

Js²,

Rh³

et al. 2010

J Natl Compr Canc Netw

223

View full text Add to dashboard Cite

OverviewNon-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B-, T-, or natural killer (NK) lymphocytes. In the United States, B-cell lymphomas represent 80% to 85% of all cases, with 15% to 20% being T-cell lymphomas; NK lymphomas are very rare. In 2009, an estimated 65,980 new cases of NHL will be diagnosed and 19,500 will die of the disease.1 NHL is the sixth leading site of new cancer cases among men and fifth among women, accounting for 4% to 5% of new cancer cases and 3% to 4% of cancer-related deaths. Non-Hodgkin's Lymphomas Clinical Practice Guidelines in OncologyKey Words NCCN Clinical Practice Guidelines, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, marginal zone lymphoma, mucosaassociated lymphoid tissue lymphoma, diagnosis, treatment, hematopathology, immunohistochemistry, treatment guidelines, staging evaluation, lymphoma pathology (JNCCN 2010;8:288-334) NCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus. Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement). Category 3: The recommendation is based on any level of evidence but reflects major disagreement. Please NoteThese guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of the NCCN © 2010. Disclosures for the NCCN Non-Hodgkin's Lymphomas Guidelines PanelAt the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.Individual disclosures for the NCCN Non-Hodgkin's Lymphomas Guidelines Panel members can be found on page 334. (To view the most recent version of these guideli...

show abstract

“…The autoantibodies may be produced by neoplastic B-cells themselves (10). On the other hand, in some cases of AIHA and cold agglutinin disease associated with B-cell chronic lymphocytic leukemia, there is evidence that the autoantibodies are produced by reactive polyclonal B cells that have undergone somatic hypermutation (3,11,12). In the present case, it seems unlikely that the neoplastic B cells carrying t(14;18) were capable of producing antibodies directed against three-lineage blood cells.…”

Section: Discussionmentioning

confidence: 99%

“…Rituximab, a monoclonal antibody for the CD20 antigen, has been introduced into the treatment of immune cytopenia with the aim to eliminate antibody-producing B cells (2)(3)(4). In one retrospective series of Evans syndrome, the long-term response rate to rituximab was reported to be 64%, and the use of rituximab for corticosteroid-resistant cases was warranted (1).…”

Section: Introductionmentioning

confidence: 99%

Immune Pancytopenia Associated with a Leukemic B-Cell Tumor Carrying t(14;18)(q32;q21) Translocation

et al. 2011

View full text Add to dashboard Cite

We report a 75-year-old man who was initially suggested to have acute leukemia. The hemoglobin level was 3.8 g/dL, white cell count was 7,700/μL with an absence of mature neutrophils and 69.0% leukemic cells, and platelet was 0. The bone marrow consisted of normal hematopoietic precursors, whereas fluorescence in situ hybridization detected the BCL2/IgH fusion gene. He was treated with rituximab-containing chemotherapy, resulting in the resolution of pancytopenia. The underlying disease was a leukemic B-cell tumor with t(14;18)(q32;q21), and the pancytopenia was mainly caused by autoimmune mechanisms.

show abstract

Rituximab for the treatment of autoimmune cytopenias

Cited by 25 publications

References 87 publications

Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphomas

Non-Hodgkin’s Lymphomas

Immune Pancytopenia Associated with a Leukemic B-Cell Tumor Carrying t(14;18)(q32;q21) Translocation

Contact Info

Product

Resources

About